Eris Lifesciences to acquire Onabet, Halobate and 7 other dermatology brands from Glenmark Pharma for over Rs 338 crore

Published On 2023-01-19 06:15 GMT   |   Update On 2023-01-19 06:16 GMT
Advertisement

Bengaluru: Indian drugmaker Eris Lifesciences Ltd said on Tuesday it would acquire a portfolio of dermatology brands from Glenmark Pharmaceuticals Ltd for 3.4 billion rupees ($41.63 million) to deepen its presence in the anti-fungal and anti-psoriasis segments.

The deal, through Eris' dermatology-focused unit, is for the purchase of nine brands, including Onabet, Halobate, Sorvate, and Demelan for India and Nepal, Eris said.

Advertisement

Glenmark said, post divestiture of the brands, it will further consolidate its position in the core therapeutic areas of cardiometabolic, respiratory, dermatology, and oncology segments.

Read also: Glenmark Pharma unveils lower cost alternative to Bumex Injection

The deal for the portfolio that has an annual revenue base of 850 million rupees, will be financed through borrowings, and the transaction is expected to achieve financial closure very soon, Eris said.

Separately, Eris on Tuesday reported a consolidated net profit of 1.02 billion rupees in its third quarter, from 1.01 billion rupees a year earlier

Read also: Eris Lifesciences to acquire Oaknet Healthcare for Rs 650 crore



Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News